Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The study evaluated the activity of ceftolozane-tazobactam (C/T) against 94 unique clinical isolates of complex (ECC). No difference was observed according to the ECC cluster. The activity greatly varied depending on the β-lactamase-producing profile: 100%, 67%, and 19% of wild-type, extended-spectrum β-lactamase (ESBL)-producing, and AmpC-overproducing strains, respectively, were susceptible to C/T. The use of C/T could be of interest for the treatment of some infections caused by ESBL-producing AmpC-nonoverexpressing ECC isolates.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125531 | PMC |
| http://dx.doi.org/10.1128/AAC.00675-18 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antimicrobial resistance profiles in multidrug-resistant Pseudomonas aeruginosa isolates in a university hospital in Argentina. Activity of new antibiotic combinations.
Rev Argent Microbiol
September 2025
Laboratorio de Bacteriología, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, INFIBIOC, UBA, Buenos Aires, Argentina.
Thirty consecutive multidrug-resistant non-carbapenemase-producing Pseudomonas aeruginosa clinical isolates from patients admitted at a university hospital were studied. Resistance rates to ceftazidime/avibactam, aztreonam/avibactam, ceftolozane/tazobactam and imipenem/relebactam were 40%, 88%, 3%, and 20%, respectively. Ceftazidime/avibactam reverted ceftazidime resistance in 25% of the isolates, whereas imipenem/relebactam did so in 77% of the imipenem-resistant isolates.
View Article and Find Full Text PDFPooled data from phase 3 clinical trials comparing the clinical activity of ceftolozane/tazobactam versus meropenem for the treatment of complicated intra-abdominal infections.
Infect Dis (Lond)
September 2025
Department of Hepatobiliary Surgery, The First Hospital of Kunming, Kunming, China.
Background: Ceftolozane/tazobactam (C/T) in combination with metronidazole is an active antimicrobial therapy used to treat complicated intra-abdominal infections (cIAIs).
Methods: A comparison of the clinical efficacy of C/T plus metronidazole vs. meropenem for the treatment of cIAIs using pooled data from four phase 3 clinical studies (CXA-cIAI-10-08, CXA-cIAI-10-09, NCT02739997 and NCT03830333).
Longitudinal molecular epidemiology of ceftriaxone-resistant enterobacterales in intra-abdominal and urinary tract infections: A decade-long SMART surveillance study in Taiwan (2009-2019).
J Microbiol Immunol Infect
August 2025
Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, And College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address:
Background: Third-generation cephalosporin-resistant Enterobacterales is a recognized global concern. This study investigated the molecular epidemiology of β-lactamase genes and antimicrobial susceptibility patterns among ceftriaxone-resistant Enterobacterales causing intra-abdominal and urinary tract infections in Taiwan between 2009 and 2019.
Methods: Data from the SMART surveillance program were analyzed, including Enterobacterales isolates with ceftriaxone minimum inhibitory concentrations ≥4 μg/mL.
[Beta-lactams and beta-lactamase inhibitors-current developments].
Inn Med (Heidelb)
August 2025
Institut für medizinische Mikrobiologie, Universität Bochum, Bochum, Deutschland.
Numerous new developments in antibacterial substances have been observed in recent years. Most of these are further developments of existing classes, especially beta-lactams, including beta-lactamase inhibitors. These included MRSA-active cephalosporins (ceftaroline and ceftobiprole), new, broadly effective combinations of beta-lactams with beta-lactamase inhibitors, and cefiderocol, a new siderophore cephalosporin that uses the bacteria's own iron uptake systems of gram-negative bacteria to better reach the site of action through the outer membrane.
View Article and Find Full Text PDFGram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).
J Antimicrob Chemother
August 2025
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada R3E 0J9.
Objectives: CANWARD is a Canadian Antimicrobial Resistance Alliance (CARA)/Health Canada partnered national surveillance study established in 2007 to annually assess the in vitro activities of commonly tested and recently approved antimicrobial agents for bacterial pathogens isolated from patients receiving care in Canadian hospitals.
Methods: In total, 34 155 Gram-negative pathogens were tested using the CLSI reference broth microdilution method.
Results: In total, 39.